Overview

International, Multicenter, Open-Label and Randomized Withdrawal Study of Oral Lixivaptan in Heart Failure Patients With Chronic Hyponatremia

Status:
Withdrawn

Trial end date:
2010-12-01

Target enrollment:

Participant gender:

Summary

To demonstrate that after 12 weeks of open-label lixivaptan treatment, serum sodium is maintained in hyponatremic patients continuing to receive lixivaptan compared to placebo during the 4 week double blind treatment period.

Phase:

Phase 3

Details

Lead Sponsor:

CardioKine Inc.

Collaborators:

Biogen
Cardiokine Biopharma, LLC